Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Nanus

Showing results (1-10 of 168) with videos related to

Pageof 17
Sort By:
The Urologic Clinics of North America|September 5, 2003
Chemotherapeutic strategies for renal cell carcinomaMatthew I Milowsky, David M Nanus
F1000 Medicine Reports|October 16, 2010
Recent advances in management of renal cancerJay H Shah, David M Nanus
F1000Research|March 29, 2016
Recent advances in the management of renal cell carcinomaAna M Molina, David M Nanus
Biochimica Et Biophysica Acta|August 2, 2005
Involvement of neutral endopeptidase in neoplastic progressionMakoto Sumitomo, Ruoqian Shen, David M Nanus
Cancer Research|September 19, 2012
Androgen receptor on the move: boarding the microtubule expressway to the nucleusMaria Thadani-Mulero, David M Nanus, Paraskevi Giannakakou
Journal of Visualized Experiments : Jove|June 5, 2014
In vitro method to observe E-selectin-mediated interactions between prostate circulating tumor cells derived from patients and human endothelial cellsGunjan Gakhar, Neil H Bander, David M Nanus
Journal of Cancer Metastasis and Treatment|May 1, 2018
Using circulating tumor cells to advance precision medicine in prostate cancerGiuseppe Galletti, Daniel Worroll, David M Nanus, et al.
International Journal of Oncology|August 17, 2012
Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancerKatsuyuki Iida, Rong Zheng, Ruoqian Shen, et al.
The Journal of Biological Chemistry|January 6, 2004
Direct binding of neutral endopeptidase 24.11 to ezrin/radixin/moesin (ERM) proteins competes with the interaction of CD44 with ERM proteinsAkira Iwase, Ruoqian Shen, Daniel Navarro, et al.
Current Research in Biotechnology|January 27, 2022
Highly portable quantitative screening test for prostate-specific antigen at point of careBalaji Srinivasan, David M Nanus, David Erickson, et al.
Pageof 17

Showing results (1-10 of 168) with videos related to

Sort By:
Pageof 17
The Urologic Clinics of North America|September 5, 2003
Chemotherapeutic strategies for renal cell carcinomaMatthew I Milowsky, David M Nanus
F1000 Medicine Reports|October 16, 2010
Recent advances in management of renal cancerJay H Shah, David M Nanus
F1000Research|March 29, 2016
Recent advances in the management of renal cell carcinomaAna M Molina, David M Nanus
Biochimica Et Biophysica Acta|August 2, 2005
Involvement of neutral endopeptidase in neoplastic progressionMakoto Sumitomo, Ruoqian Shen, David M Nanus
Cancer Research|September 19, 2012
Androgen receptor on the move: boarding the microtubule expressway to the nucleusMaria Thadani-Mulero, David M Nanus, Paraskevi Giannakakou
Journal of Visualized Experiments : Jove|June 5, 2014
In vitro method to observe E-selectin-mediated interactions between prostate circulating tumor cells derived from patients and human endothelial cellsGunjan Gakhar, Neil H Bander, David M Nanus
Journal of Cancer Metastasis and Treatment|May 1, 2018
Using circulating tumor cells to advance precision medicine in prostate cancerGiuseppe Galletti, Daniel Worroll, David M Nanus, et al.
International Journal of Oncology|August 17, 2012
Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancerKatsuyuki Iida, Rong Zheng, Ruoqian Shen, et al.
The Journal of Biological Chemistry|January 6, 2004
Direct binding of neutral endopeptidase 24.11 to ezrin/radixin/moesin (ERM) proteins competes with the interaction of CD44 with ERM proteinsAkira Iwase, Ruoqian Shen, Daniel Navarro, et al.
Current Research in Biotechnology|January 27, 2022
Highly portable quantitative screening test for prostate-specific antigen at point of careBalaji Srinivasan, David M Nanus, David Erickson, et al.
Pageof 17